Citations

Clear

1152 citation(s) found for "Todd, A".

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Wen, Patrick Y. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Groot, John de , Lim, Michael, Mellinghoff, Ingo K. , Perry, James, Weller, M, Blondin, Nicholas A., Butt, Omar H. , Damek, Denise M., Fuente, Macarena I. de la , Drappatz, Jan, Dunbar, Erin, Giglio, Pierre , Hyddmark, Emma Viktoria, Iwamoto, Fabio, Jaeckle, Kurt A. , Kim, Lyndon, Kling, Heather M., Lee, Eudocia Q., Mantica, Megan , Mikkelsen, Tom, Newton, Herbert B. , Walbert, Tobias , Weathers, Shiao‐Pei , Lassman, Andrew B. , Group, for the GBM AGILE Regorafenib Study, Alexander, Brian, Anker, Lars , Berry, Nicholas , Cloughesy, Tim, Connelly, Jennifer , Detry, Michelle A. , Fitzgerald, Mark, Gordon, Gary, Graves, Todd, Hu, Jethro , Hyddmark, Emma Maria Viktoria, Johnson, Adam, Kalabic, Marija, Lesser, Glenn J., Marion, Joe , Owen, Scott, Perry, James R, Peters, Katherine B., Powell, Ashley, Saunders, Christina T., Tanner, Kirk, Untch, Sarah, Wilcox, Emma, Yung, W. K. Alfred, Lim, Michael , Buxton, Meredith , de Groot, John , Mellinghoff, Ingo K , Weller, Michael , De La Fuente, Macarena , Lee, Eudocia Q , Mantica, Megan , Nabors, Louis Burt , Newton, Herbert B , Olson, Jeffrey J. , Schiff, David , Walbert, Tobias , Weathers, Shiao-Pei , Cloughesy, Timothy F , Lassman, Andrew B , Berry, Donald , Colman, Howard , Blondin, Nicolas, Drappatz, Jan , Iwamoto, Fabio M., Lee, Eudocia Q. , Mikkelsen, Tom , Nabors, Burt , Newton, Herbert B. , Cloughesy, Timothy F. , Anderson, Mark D., Cavenee, Webster K. , Connelly, Jennifer , Ellingson, Benjamin M. , Galanis, Evanthia , Gordon, Gary, Graber, Jerome J. , Khasraw, Mustafa , Lesser, Glenn J. , McGlothlin, Anna , Peters, Katherine B. , Saunders, Christina T. , Sulman, Erik P. , Tanner, Kirk, Yung, W.K. Alfred

Mayo Clinic

Journal of Clinical Oncology | April 14, 2026 | Volume: 44 | Issue: 18 | Pages: 1676-1686

10.1200/jco-25-01137 | PMID 41980234 Get It

PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
Development and cross-site validation of machine-learning models for diagnosis and prognosis of stable angina with and without obstructive coronary artery disease: a study protocol
Deng, Jiawen, Patel, Shubh , Fung, Marinda, Heybati, Kiyan , Layard, Briana, Wang, Bo, Rubin, B., Hibbert, Benjamin, Anderson, Todd, Deng, Jiawen , Patel, Shubh K , Subasri, Vallijah , Deng, J , Simard, Trevor , Anderson, Todd J.

Mayo Clinic

BMJ Open | April 8, 2026 | Volume: 16 | Issue: 4 | Pages: e108799

10.1136/bmjopen-2025-108799 | PMID 41951258 Get It

Introduction Angina with no obstructive coronary artery disease (ANOCA) affects millions and is frequently under-recognised because diagnostic pathways and risk tools predominantly target obstructive coronary artery disease (CAD). This protocol describes shared methods for two machine-learning (ML) studies: (1) differentiating ANOCA from stable angina with obstructive CAD and (2) predicting long-term mortality among patients with ANOCA and obstructive CAD. Methods and analysis We will develop and cross-site validate ML classification models using a multicentre retrospective cohort drawn from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry and institutional datasets from the University of Ottawa Heart Institute and the University Health Network. Eligible participants are adults (≥18 years) undergoing initial cardiac catheterisation for chest pain/anginal equivalents since 1995, excluding prior revascularisation, major structural heart disease and predefined non-anginal indications. Outcomes are (1) ANOCA (0% to <50% stenosis) versus obstructive CAD (≥50% stenosis) and (2) 1, 3 and 5-year mortality, modelled separately for ANOCA and obstructive CAD. Model development will use nested cross-validation with stratified k-fold inner-loop tuning and leave-one-site-out cross-validation for repeated external validation. Candidate predictors will be harmonised across sites, filtered for missingness and refined using expert/directed acyclic graph-guided selection plus Boruta and Least Absolute Shrinkage and Selection Operator. Preprocessing includes appropriate encoding, missing-data imputation (multivariate imputation by chained equations) and feature scaling. Algorithms will include elastic-net logistic regression, random forest, LightGBM and multilayer perceptron models; hyperparameters will be optimised via Bayesian optimisation. Performance and threshold tuning will be reported. Explainability and subgroup fairness will be assessed using SHapley Additive exPlanations. Final models will be deployed as a web-based clinical risk calculator. Ethics and dissemination Ethics approval has been obtained from the University of Calgary and the University Health Network (#24-5916). Analyses will use deidentified data in secure environments; only aggregate results will be reported. Findings will be disseminated via peer-reviewed publications, conferences and a web-based calculator.
Toward actionable interventions in human aging (12th ARDD meeting, 2025)
Dekan, Aleksandr , Lore, Sierra , Yoon, Ye Eun, Sjöholm, Aisyah, Terskikh, Alexey V. , Cuervo, A. M., Georgievskaya, Anastasia , Heinz, Andrea , Adams, Andrew, Tsai, Andy P. , Murray, Anna, Brunet, Anne , Harten, Anne Marije van, Spier, Avi, Shenhar, Ben , Clasen, Berthil, Volbracht, Christiane , Kuppe, Christoph, Cookson, Clive, Banila, Cristiana , Cai, Daisy, Lamming, Dudley W. , Rudnic, Edward, Samra, Elias Bou , Verdin, Eric, Fagagna, Fabrizio d’Adda di, Zmudze, Garri, Jasper, Heinrich, Jang, In Hwa, Lemaitre, J. M., Betts-LaCroix, Joe , Newman, John C. , Kawamura, Kazuto , Schaal, Kennedy Matsagas, Egerton, Kitsu, Fortney, Kristen , Hartenstein, Lars, Niedernhofer, Laura, Katsimpardi, Lida , Melton, Lisa , Ferrucci, Luigi, Sylow, Lykke, Demaria, Marco , Guasch-Ferré, Marta, Borch-Jensen, Martin, Kholin, Maxim, Antonov, Michael, Deleidi, Michela , Mérad, Miriam , Meldal, Morten, Topors, Mourad, Venkatesan, Murali, LeBrasseur, Nathan K., Anzinger, Niklas, Fedichev, Peter O, Kohlhaas, Paul, Mullen, Peter J., Singhal, Priya , Cabo, Raquel, Montgomery, Rusty L. , Rosenzweig-Lipson, Sharon, Jakimov, Sergey, Austad, Steven N. , White, Todd, Zuber, Tom, Rozmaric, Tomaz , Wyss-Coray, Tony, Gladyshev, Vadim N., Sinatti, Vanessa V. C., Wang, Weilan, Harborne, William, Wang, Xing Li, Suh, Yousin , Lee, Y., Koch, Zane, Scheibye-Knudsen, Morten, Niedernhofer, Laura J. , Wyss‐Coray, Tony , Niedernhofer, Laura J , Lamming, Dudley W , Deleidi, Michela , Wyss-Coray, Tony , Bakula, Daniela , Tyshkovskiy, Alexander , Cuervo, Ana M , Seluanov, Andrei , Murray, Anna , Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Suetta, Charlotte , Kuppe, Christoph , Ewald, Collin Y. , Valenzano, Dario Riccardo , Rudnic, Edward M., Teeling, Emma C. , Verdin, Eric , Fang, Evandro Fei , Fagagna, Fabrizio d’Adda di , Galkin, Fedor , Jasper, Heinrich , Jang, In Hwa , Han, Jing‐Dong J. , Justice, Jamie N. , Hoeijmakers, Jan H.J. , Ramos, Javier María Peralta , Lemaı̂tre, Jean-Marc , Aerssens, Jeroen , Belmonte, Juan Carlos Izpisúa , Abdelmohsen, Kotb , Knudsen, Lotte Bjerre , Ferrucci, Luigi , Sylow, Lykke , Schafer, Marissa , Guasch‐Ferré, Marta , Levitt, Michael R. , Meldal, Morten , Fedichev, Peter O. , Mullen, Peter J. , Cabo, Rafael de, Houtkooper, Riekelt H. , Smith, Ryan , Rosenzweig‐Lipson, Sharon, Horvath, Steve , Rando, Thomas A. , White, Todd, Tammela, Tuomas , Gladyshev, Vadim N. , Sinatti, Vanessa V C , Liu, Xiaodong , Suh, Yousin , Koch, Zane , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | April 6, 2026 | Volume: 18 | Issue: 1 | Pages: 282-302

10.18632/aging.206368 | PMID 41944812 Get It

Traumatic brain injury recovery prediction by harmonizing real brain CT and synthetic brain MRI: a pilot study
Che, Yiming , Joshi, Amogh Manoj , Shah, Jay , Siddiquee, Md Mahfuzur Rahman , Nikolova, Simona , Li, Baoxin, Rahman Siddiquee, Md Mahfuzur , Chong, Catherine D. , Dumkrieger, Gina , Wu, T. John , Schwedt, Todd J.

Mayo Clinic

Brain Communications | April 3, 2026 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcag123 | PMID 42004011 Get It

Abstract To enhance the prediction of traumatic brain injury (mTBI) outcomes, we propose a deep learning approach that integrates brain computed tomography (CT) scans with corresponding synthetic T1-weighted magnetic resonance imaging (T1-MRI). Our method significantly outperforms the prediction using CT scans alone. TRACK-TBI Pilot dataset, which includes imaging and clinical outcome data from patients with TBI, is studied. The hypothesis is brain CT and T1-MRI complement each other and together will improve TBI prognosis compared to using either CT or T1-MRI alone. Since CT and T1-MRI may not be available for the same individual, we employed a specialized version of a generative adversarial network (GAN), known as fixed-point GAN (FP-GAN). FP-GAN was trained using unpaired CT and T1-MRI scans to generate synthetic T1-MRIs from real CT scans. This process produced pseudo-paired CT-MRI data, which was then used to train a deep learning classifier for outcome prediction. The classifier consists of dual parallel 3D ResNet-18 models, each independently processing T1-MRI and CT scans. We used Glasgow Outcome Scale-Extended (GOSE) scores at 3 months post-TBI as the measure of patient outcomes. To avoid data leakage, the subjects used in FP-GAN and ResNet-18 model have no overlap. We further divided the paired data, allocating 69 samples for 5-fold cross-validation and 17 samples for testing. Prognostic performance was evaluated using the area under the receiver operating characteristic curve (AUC), F1-score (the harmonic mean of precision and recall), sensitivity (true positive rate) and specificity (true negative rate). For binary classification, we defined good recovery as GOSE ≥ 7 (positive) and poor recovery (negative) as 3 ≤ GOSE ≤ 6. Accordingly, our training set consists of 24 subjects with poor recovery and 45 subjects with good recovery, while the testing set includes 5 subjects with poor recovery and 12 subjects with good recovery. A DeLong test on AUC confirms that the improvement from incorporating synthetic T1-MRI (AUC = 0.76 ± 0.10) is statistically significant (P &lt; 0.05) compared to using CT alone (AUC = 0.68 ± 0.13). The significant improvement from using the combination of real CT and synthetic T1-MRI in sensitivity (SEN = 0.95 ± 0.07) and overall performance metrics, such as F1-score (F1 = 0.84 ± 0.03), suggests that the proposed approach provides a robust and effective prognostic approach compared to using CT alone (SEN = 0.83 ± 0.18 and F1 = 0.76 ± 0.07). This pilot research demonstrates the potential of a deep learning-based harmonization model to bridge the gap between CT and T1-MRI in TBI assessment. By integrating synthetic T1-MRI with CT, prediction performance is substantially enhanced.
Neurodegeneration risk variants promote lysosomal TMEM106B fibril accumulation
Replogle, John, Marks, Jordan D. , Fernandez, Martin G , Yu, Dahyun , Winters, Elizabeth, Jawahar, Vidhya Maheswari, Deshmukh, Rishi, Sutanto, Renaldo, Kowal, Isabelle, Frankenfield, Ashley M. , Shi, Rachel , Carlomagno, Yari , Jansen-West, Karen, Kopach, Andrii , Ndayambaje, I. Sandra , Qi, Yue Andy, Shantaraman, Ananth, Pozo-Cabanell, Ignacio, Sheth, Udit , Yue, Mei, Duong, Duc, Bennett, David A, Damme, Markus, Boeve, Brad F, Day, Gregory S, Skarnes, William C, Petersen, Ronald C, Josephs, K., Graff-Radford, Neill, Barmada, Sami J. , Zhang, Yongjie, Hao, Ling , DeTure, Michael , Rawlinson, Bailey, Cook, Erica Engelberg, Casey, Monica Castanedes, Perez, Nathan M, Dickson, Dennis, Liu, Yue, Seyfried, Nicholas T., Wingo, Thomas S, Mosalaganti, Shyamal , Petrucelli, Leonard, Ward, Michael E, Ward, Michael E. , Replogle, John Michael , Todd, Tiffany W. , Engelberg-Cook, Erica , Perez, Nathan, Ward, Michael E , Barmada, Sami , Sheth, Udit , Yuan, Hebao , Kowal, Isabelle , Jansen‐West, Karen , Qi, Yue , Shantaraman, Anantharaman , Duong, Duc, Ferguson, Shawn M. , Bennett, David A. , Daμμe, Markus , Day, Gregory S. , Kellman, Benjamin P. , Skarnes, William C. , Petersen, Ronald C. , Graff‐Radford, Neill R. , McDonough, Justin A. , Prudencio, Mercedes , Dickson, Dennis W. , Wingo, Aliza P. , Liu, Yue, Seyfried, Nicholas T. , Wingo, Thomas S , Petrucelli, Leonard

Mayo Clinic

No container title available | March 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.26.714634 | PMID 41929000 Get It

Variants in TMEM106B and GRN , which encode lysosomal proteins, interact through unknown mechanisms to increase the risk of age-related cognitive decline and neurodegeneration. Here, we show that these variants converge on a single molecular intermediate: the cleaved intra-lysosomal fibril core of TMEM106B, a precursor to amyloid fibrils that accumulate in the aging brain. A protein-coding TMEM106B risk variant (p.T185) drives fibril core accumulation by impairing its degradation and GRN risk variants amplify this effect. Mice over-expressing the fibril core develop hallmarks of neurodegeneration, and cryo-electron tomography reveals intra-lysosomal fibrils in cultured neurons, mice, and diseased human brain. In GRN -mutation carriers, in whom fibril burden is greatest, fibrils extrude through ruptured lysosomal membranes. These findings identify intra-lysosomal TMEM106B fibrillization as a convergent neurodegeneration mechanism and potential therapeutic target.
Minimal Clinically Important Difference of the Sinonasal Outcome Test in Sinonasal Malignancy
Maoz, Sabrina L. , Lee, Michelle , Fischer, Jakob L. , Choby, Garret M., Hwang, Peter H. , Wang, En, Adappa, Nithin D., Getz, Anne E., Humphreys, Ian M. , Pinheiro-Neto, Carlos D., Chan, Erik, Roozdar, Pooya, Chang, Eugene H., Jafari, Aria, Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne T. , Lazor, Jillian W. , Nabavizadeh, Ali, Palmer, James N., Patel, Zara M. , Smith, Tim L., Snyderman, Carl H., John, Maie A. St, Storm, Phillip B., Wang, Marilene B., Sim, Myung‐Shin , Beswick, Daniel M., Fischer, Jakob Louis , Humphreys, Ian M , Chang, Eugene H , Snyderman, Carl H , Patel, Zara , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Kuan, Edward C , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Pinheiro‐Neto, Carlos , Abuzeid, Waleed M. , Chang, Eugene H. , Jafari, Aria , Nayak, Jayakar V. , Adappa, Nithin D. , Resnick, Adam , John, Maie A. St., Storm, Phillip B. , Suh, Jeffrey D. , Beswick, Daniel M.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | March 26, 2026 | Volume: 135 | Issue: 7 | Pages: 543-549

10.1177/00034894261428393 | PMID 41881811 Get It

Background: Sinonasal malignancies (SNM) are rare cancers associated with poor prognosis and impaired quality of life (QOL). The 22-question Sino-Nasal Outcome Test (SNOT-22) has been used to assess QOL in patients with SNM. Objective: To determine the minimal clinically important difference (MCID) for the SNOT-22 in patients with SNM. Methods: About 264 patients with SNM were drawn from a prospective, longitudinal, multi-institutional study. SNOT-22 scores were collected at pre-treatment baseline and follow-up through 5 years post-treatment. Cronbach’s alpha was used to assess the internal consistency of the SNOT-22. Distribution-based approaches were used to estimate the MCID. Multivariable regression identified factors associated with SNOT-22 improvement exceeding the determined MCID. Results: Cronbach’s alpha was >.85. The estimated MCIDs were: 1.44 (Cohen’s effect size), 1.32 (standard error of the mean), 10.45 (1/2 of baseline standard deviation), and 3.67 (minimum detectable change). The mean MCID across methods was 4.22. Multivariable regression demonstrated higher odds of clinically meaningful improvement from baseline in patients with early-stage disease (odds ratio (OR) 3.510, P = .035), no neck irradiation (OR 11.050, P = .014), and neoadjuvant therapy (OR 16.667, P = .047). Conclusions: The SNOT-22 MCID was estimated as 4.22 in a large multi-center cohort of patients with SNM, suggesting that relatively small QOL changes are clinically relevant. When applying the MCID to the current cohort, advanced stage, treatment of neck disease, and not requiring neoadjuvant therapy were predictive of worse QOL.
NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas
Butt, Omar H. , Singhal, Kartik , Luo, Jingqin , Rettig, Michael P. , Foltz, Jennifer A. , Huang, Jiayi , Zhou, Alice Y. , Tao, Yu , Griffith, Obi L., Griffith, Malachi, Johanns, Tanner M. , Ansstas, George , Zhang, Chaocai , Tang, Justin , Christ, Stephanie , Ferrando-Martinez, Sara , Lee, Byung Ha , Chheda, Milan G., Fehniger, Todd A. , Campian, Jian L., Griffith, Malachi , Griffith, Obi L. , Huang, Jiayi , Griffith, Obi L , Griffith, Malachi , DiPersio, John F , Chheda, Milan G , Fehniger, Todd A , Campian, Jian L , Luo, Jingqin , Ansstas, George , DiPersio, John F. , Chheda, Milan G. , Campian, Jian

Mayo Clinic

Clinical Cancer Research | March 25, 2026 | Volume: 32 | Issue: 13 | Pages: 2581-2592

10.1158/1078-0432.ccr-25-2953 | PMID 41880597 Get It

Abstract Purpose: Standard care for high-grade gliomas (HGG) involves maximal surgical resection followed by radiation and temozolomide. Postoperative adjuvant therapy frequently causes lymphopenia, which is associated with poor prognosis. Interleukin 7 (IL7) is essential for lymphocyte development, homeostasis, and survival. NT-I7 (efineptakin alfa), a long-acting recombinant IL7, reverses lymphopenia and improves survival in murine glioma models. However, the safety, maximum tolerated dose (MTD), and impact of NT-I7 on immune cells in patients with HGG remain unknown. Patients and Methods: We conducted a phase I trial (NCT03687957) examining the MTD and effect of NT-I7 on lymphocytes in patients with newly diagnosed HGG. The primary endpoint was dose-limiting toxicity; secondary endpoints included absolute lymphocyte count (ALC) changes over time, overall response, progression-free survival, and overall survival. Exploratory endpoints included immune profiling at different time points using single-cell RNA sequencing (scRNA-seq) in a subset of patients. Results: NT-I7 was well tolerated with a MTD of 720 µg/kg. Moreover, NT-I7 significantly increased ALCs for more than 12 weeks in duration. Early elevations in CD4+, CD8+ T cells and NK cells further coincided with increased TNF and CXCL9 cytokine levels. Comprehensive immune profiling of peripheral blood T cells revealed selective clonotype expansion within CD8+, but not CD4+, T cells following NT-I7 administration. Finally, a subset of our patients with MGMT promoter–unmethylated glioblastoma, which are typically associated with a poorer prognosis, demonstrated promising clinical responses. Conclusions: NT-I7 has the potential to maintain and increase lymphocyte counts in patients with HGG and warrants further investigation, particularly in combination with immune-based therapies.
AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results From the Multicenter STOMP2 Trial
Schwartz, David A., Dozois, Eric J. , Ehman, Eric C. , Faubion, W, Hudesman, David, Pabla, Baldeep , Papadakis, K, Fleshner, Phillip, Dozois, Eric, Ehman, Eric , Faubion, William , Papadakis, Konstantinos , Schwartz, David A. , Hudesman, D, Johnson, Todd , Fleshner, Phillip

Mayo Clinic

American Journal of Gastroenterology | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004005 | PMID 41879234 Get It

INTRODUCTION: Advanced therapies infrequently achieve complete fistula closure in patients with Crohn's disease (CD). The primary objective of the STOMP2 clinical trial was to determine whether the implantable autologous cell therapy AVB-114 is effective in inducing remission of persistent Crohn's perianal fistulas versus standard of care. METHODS: Eligible patients had a single perianal fistula tract and had failed previous treatment or had documented medication intolerance to biologic or conventional CD therapy. All enrolled subjects underwent surgical fistula optimization and adipose tissue biopsy collection (to manufacture AVB-114) followed by 1:1 randomization to either standard of care (repeat fistula optimization including seton replacement) or AVB-114 implantation. The primary end point was combined fistula remission at 36 weeks, defined as closure of the external opening, no drainage of fluid despite gentle finger compression, and no collections >2 cm in at least 2 of the 3 dimensions on MRI. RESULTS: Subjects at 14 US sites were equally randomized to SoC (N = 24) or AVB-114 (N = 24). Week 36 combined remission was 8.3% and 45.8% for subjects randomized to SoC and AVB-114, respectively (38% difference, 95% CI 11%–60%; P = 0.0078). At week 36, MRI revealed no subjects with collections >2 cm, radiological improvement (≥50% decrease in the Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease (MAGNIFI-CD) score from baseline) in 1 SoC subject and 3 AVB-114 subjects, and radiological healing (complete resolution of T2-weighted hyperintensity in fistula tract) in 2 SoC subjects and 5 AVB-114 subjects. Through week 36, there were 40 and 56 treatment emergent adverse events for SoC and AVB-114, respectively. There were no serious treatment emergent adverse events in the AVB-114 group through week 36. DISCUSSION: A significantly higher proportion of patients treated with AVB-114 achieved combined remission vs SoC, and the treatment was well tolerated. These data support the safety and efficacy of AVB-114 in persistent Crohn's perianal fistulas.
Remote Patient Monitoring Process Improvement
Boynton, Bradley, Folkerts, Karla, Meyer, Todd J., Staff, Nathan P.

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 66 | Issue: 10_suppl | Pages: 3606046-3606046

10.4187/respcare.20213606046 Get It

An intra-patient contemporaneous comparison of 18 F-piflufolastat and 18 F-flotufolastat urinary radioactivity and local and pelvic region detection rates
Helfand, B.R., Andrews, Jack R. , Kuo, Phillip H. , Gartrell, Benjamin A. , Josephson, David, Saltzstein, Daniel R. , Pathak, Ram , Shore, Neal D., Sykes, James, Penny, Ross, Cohen, Todd, Nordquist, Luke, Purysko, Andrei Saraiva , Shore, Neal D. , Penny, Ross

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 32-32

10.1200/jco.2026.44.7_suppl.32 Get It

32 Background: PET-based radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have become the mainstay of prostate cancer imaging; however, high urinary radioactivity from these primarily renally cleared compounds may obscure tumors in the prostate and peri-ureteric regions. We conducted the first intra-patient comparator study to assess the urinary radioactivity of two 18 F-labelled PSMA-PET radiopharmaceuticals, 18 F-piflufolastat and 18 F-flotufolastat. Methods: This multicenter, prospective, intra-patient comparator study (NCT06604442) enrolled men ≥ 18 years with low PSA (≤ 0.5 ng/mL) biochemical recurrence of prostate cancer ≥ 6 months after radical prostatectomy with undetectable PSA post-surgery, scheduled for a standard-of-care (SoC) 18 F-piflufolastat PET. Patients had a SoC PET/CT after IV 18 F-piflufolastat (target dose 333 MBq), and a second PET/CT 1–10 days later after IV 18 F-flotufolastat (target dose 296 MBq), both scans started approximately 60 min after administration and used the same scanner. The primary endpoint was the difference in urinary bladder radioactivity (mean standardized uptake value [SUV mean ]) between 18 F-piflufolastat PET and 18 F-flotufolastat PET. Secondary endpoints included patient and region-level detection rates (DR) for each radiopharmaceutical. Images were interpreted by two blinded central readers, with a third to resolve disagreements, allowing majority read results. Results: Between Oct 2024 and Jun 2025, 55 patients (mean PSA, 0.28 [range 0.09–0.50] ng/mL) were included in the primary efficacy analysis. Median bladder SUV mean was significantly higher with 18 F-piflufolastat (29.0; interquartile range [IQR], 18.9–40.8) than 18 F-flotufolastat (10.9; IQR, 6.0–18.5) with a median difference of 15.1 (IQR, 8.5–27.0; p<0.001 [Wilcoxon signed-rank test]). The patient-level DR was 27.3% (15/55) for 18 F-piflufolastat and 45.5% (25/55) for 18 F-flotufolastat (majority read). Among the 21 patients with very low PSA levels (≤ 0.2 ng/mL), 38.1% had a positive 18 F-piflufolastat scan compared with 52.4% for 18 F-flotufolastat scans (majority read). Regional and sub-regional DRs are shown in the table. Conclusions: In this intra-patient study, 18 F-flotufolastat showed significantly lower urinary radioactivity, and a higher overall DR than 18 F-piflufolastat indicating it may offer improved image assessment in regions close to the bladder. Clinical trial information: NCT06604442 . Region 18 F-Piflufolastat DR* n (%)N=55 18 F-Flotufolastat DR*n (%)N=55 Prostate bed 6 (10.9) 10 (18.2) Vesicourethral anastomosis 1 (1.8) 4 (7.3) Retrovesical 2 (3.6) 2 (3.6) Remnant seminal vesicles/ lateral surgical margin 2 (3.6) 4 (7.3) Pelvic lymph nodes 8 (14.5) 9 (16.4) Majority read. *≥ 1 PET positive lesion.